LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung - Genesis Health System

Lung (Non-Small Cell) Cancer: LUNGMAP

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Objective

This study is for patients that have advanced non-small cell lung cancer and has two steps: the initial screening step where we will examine tumor tissue and the sub-study treatment step where patients will be assigned to a treatment sub-study that is chosen based on the screening results.

The purpose of the study screening step is to perform genetic tests (biomarkers) on patient tumor samples for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign patients to a treatment sub-study that is chosen based on the results (genes and proteins called “biomarkers”) of this genetic testing on the patient's tumor sample. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.

The sub-studies currently associated with the LUNGMAP screening protocol are S1900A and S1800A.

Click here for more information from the National Cancer Institute.

LOCATIONS:

1.  Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number:  563-421-1900

2.  Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3.  Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number:  563-345-4325

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email